BioLife Solutions Inc (NASDAQ:BLFS) CEO Sells $178,983.35 in Stock

BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 9,905 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $18.07, for a total value of $178,983.35. Following the completion of the transaction, the chief executive officer now owns 184,919 shares in the company, valued at approximately $3,341,486.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Rice also recently made the following trade(s):

  • On Tuesday, August 13th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.07, for a total value of $153,630.00.
  • On Tuesday, July 16th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.29, for a total value of $146,610.00.
  • On Thursday, July 18th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The shares were sold at an average price of $16.29, for a total value of $307,929.87.
  • On Tuesday, June 11th, Michael Rice sold 9,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.64, for a total value of $158,760.00.
  • On Thursday, June 13th, Michael Rice sold 18,903 shares of BioLife Solutions stock. The shares were sold at an average price of $17.37, for a total value of $328,345.11.

Shares of BLFS stock opened at $20.78 on Thursday. BioLife Solutions Inc has a 12 month low of $9.15 and a 12 month high of $26.35. The company has a quick ratio of 7.71, a current ratio of 9.42 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $17.95 and its two-hundred day moving average is $17.59. The company has a market cap of $383.86 million, a PE ratio of 148.43 and a beta of 1.37.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.59 million. As a group, equities analysts expect that BioLife Solutions Inc will post 0.1 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of BioLife Solutions in the second quarter valued at approximately $30,000. Cowen Prime Services LLC bought a new stake in shares of BioLife Solutions in the first quarter valued at approximately $63,000. Signaturefd LLC bought a new stake in shares of BioLife Solutions in the first quarter valued at approximately $161,000. Alpine Woods Capital Investors LLC bought a new stake in shares of BioLife Solutions in the second quarter valued at approximately $170,000. Finally, Morgan Stanley boosted its position in shares of BioLife Solutions by 17.5% in the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after acquiring an additional 1,713 shares during the period. 47.86% of the stock is owned by institutional investors.

Several brokerages have commented on BLFS. ValuEngine downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Maxim Group set a $24.00 price target on BioLife Solutions and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright began coverage on BioLife Solutions in a report on Monday, July 22nd. They set a “buy” rating and a $23.00 price target on the stock. Northland Securities reiterated a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a report on Tuesday, July 9th. Finally, BidaskClub upgraded BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $18.67.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: Federal Reserve

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.